Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 2;112(9):3699–3710. doi: 10.1111/cas.15024

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

(A) Average methylation levels (first row) and immunohistochemistry (IHC) scores (second row) heatmap for glioblastoma patients in the pyrosequencing (PSQ)‐defined gray zone subgroup. The MGMT status could be divided into methylated or unmethylated based on the thresholds from PSQ (threshold: 12%, third row) and IHC (threshold: 30%, fourth row). (B) IHC scores (pink line) instead of mean methylation levels (brown line) could predict overall survival (OS). (C, D) The threshold of 12% for the average methylation levels failed to assess the prognosis for gray zone, regardless of progression‐free survival (PFS) or OS. (E) The threshold for IHC score (30%) rather than the threshold for average methylation results from PSQ (12%) could effectively evaluate OS for gray zone patients. (F, G) The prognosis difference between high and low IHC scores subgroups for patients in the gray zone was significant (F, PFS; G, OS)